This knowledge led to the development of the current first-line therapies of inoperable, advanced stage melanomas targeting mediators of the ERK/MAPK pathway: RAF, MEK kinases, or the CTLA-4, PD-1/PDL-1 immune checkpoints using humanized monoclonal antibodies [1]. The gene discussed is CTLA4; the disease is melanoma.